PER — Percheron Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$6.09m
- AU$2.07m
- AU$0.15m
Brief: Percheron Therapeutics Receives Firm Commitments For A$2.3 Million Institutional Placement
Brief: Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period
Brief: Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia
Brief: Percheron Therapeutics Says James Garner To Step Down As CEO And Managing Director
Brief: Percheron Therapeutics To Raise Up To A$2.2 Million
Brief: Percheron Therapeutics Seeks Trading Halt
Brief: Percheron Therapeutics Submits Non-Binding Proposal To In-License New Clinic-Ready Drug Development Program
Brief: Percheron Therapeutics Seeks Trading Halt Pending In Relation To Initial Top Line Data For Company's Phase IIB Clinical Trial
Brief: Percheron Therapeutics Says A$13 Mln Institutional Placement At A$0.08 Per New Share
Australia's Percheron Therapeutics plunges on discounted placement
Brief: Percheron Therapeutics Seeks Trading Halt
Brief: Percheron Therapeutics Posts FY Loss Attributable Of A$11.9 Mln
Brief: Percheron Therapeutics Says Deborah Ambrosini Appointed As CFO
Brief: Antisense Therapeutics Says Share Purchase Plan Raises A$3.26 Mln
Brief: Antisense Therapeutics Says Commencement Of James Garner As CEO And Managing Director
Australia's Antisense Therapeutics falls on discounted raise to fund therapy study
Brief: Antisense Therapeutics Proposes To Launch Share Purchase Plan
Brief: Antisense Therapeutics Announces Intention To Launch Share Purchase Plan
Australia's Antisense Therapeutics hits over 3-year low on discounted placement